SYUMIX | Syntax US Medical Innovation Index

Index Description

The Syntax US Medical Innovation Index comprises up to 50 equally weighted US-listed companies engaged in the biotechnology and biopharma industry. The Index's universe of companies is maintained with the help of company classification data structured in Syntax's proprietary Functional Information System (FIS), which draws primarily from audited annual reports (e.g., SEC Form 10-K filings) and secondarily from unaudited documents (e.g., investor presentations, company websites, news articles) to allow granular groupings and comparisons of companies by the characteristics of their various product lines. To qualify, a company must pass the Index's screens for size and liquidity, and must own at least one drug that is in an FDA Phase II or Phase III trial and has a special FDA designation or a milestone in the near future.

Index Facts

Number of Constituents 50
Weighting Methodology Equal
Rebalancing Frequency Quarterly
Currency USD
Exchange Symbol/Ticker SYUMIX
Index Inception Date October 21, 2022
Base Index Value 1000
Total Return Index Value (as of 05/25/2023) 1007.05

Index Performance

Multi-Horizon Returns
(% as of 03/31/2023)
YTD1Q231Y3Y5Y7Y10YSince 10.21.22
US Medical Innovation-7.95-7.95------10.91

Top Holdings
(as of 03/31/2023)
CompanyWeight (%)
Reata Pharmaceuticals Inc5.74
BridgeBio Pharma Inc4.57
Exelixis Inc2.85
Travere Therapeutics Inc2.67
TG Therapeutics Inc2.66
Mirum Pharmaceuticals Inc2.63
Bausch Health Companies Inc2.60
Y-mAbs Therapeutics Inc2.53
Alkermes Plc2.49
ACADIA Pharmaceuticals Inc2.47